A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status

Clinical Trial to Investigate the Appropriate Dose of Isoniazid According to NAT2 Polymorphism Status in Korean Subjects

A clinical trial to investigate the appropriate dose of isoniazid according to NAT2 polymorphism status in Korean subjects

Inclusion Criteria:

• Agreement with written informed consent
• Adult healthy male or female subject age 20 to 45

Exclusion Criteria:

• Clinically significant, active gastrointestinal system, cardiovascular system, pulmonary system, renal system, endocrine system, blood system, digestive system, central nervous system, mental disease or malignancy
• Medication with any drug which may affect the pharmacokinetics of isoniazid within 14 days
• Previously donate whole blood within 30 days or Previously participated in other trial within 60 days
• Subject with known for hypersensitivity reactions to isoniazid
• Subject who can not perform contraception during study periods
• Female woman who are pregnant or are breast feeding
• An impossible one who participates in clinical trial by investigator's decision including laboratory test result